Folotyn

Active Ingredient(s): Pralatrexate
FDA Approved: * September 24, 2009
Pharm Company: * ALLOS THERAPEUTICS, INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Folotyn Overview

Pralatrexate (brand name Folotyn) is an anti-cancer therapy.[1] It is the first drug approved as a treatment for patients with relapsed or refractory peripheral T-cell lymphoma, or PTCL[2] — a biologically diverse group of aggressive blood cancers that have a poor prognosis.[2] Contents 1 Approval 2 Mechanism 3 Discovery 4 See also 5 References 6 External links Approval Folotyn was approved by the U.S. Food and Drug Administration...

Read more Folotyn Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pralatrexate

Recent Folotyn Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Folotyn: (3 results)

Sorted by National Drug Code

• 48818-001 Folotyn 20 mg/ml Intravenous Injection by Allos Therapeutics
• 72893-003 Folotyn 20 mg/ml Intravenous Injection by Acrotech Biopharma LLC
• 72893-005 Folotyn 40 mg/2ml Intravenous Injection by Acrotech Biopharma LLC

Other drugs which contain Pralatrexate or a similar ingredient: (1 result)

• PRALATREXATE

Related Folotyn Topics: